Clinicians should consider reducing doses of gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer, as a large real-world study showed worse outcomes in patients receiving modified dosing. The traditional dosing schedule of days 1, 8 and 15 of a 28-day cycle is often altered for the treatment of metastatic pancreatic cancer. It is important for clinicians to carefully consider dosing adjustments in older patients to optimize treatment outcomes and minimize potential negative effects.
Source link
Think Twice Before Dose-Reducing Gemcitabine Plus Nab-Paclitaxel
